USCOM gets FDA green light
Wednesday, 16 February, 2005
Sydney heart monitor firm USCOM (ASX:UCM) has received regulatory approval from the US Food and Drug Administration, allowing it to market its devices in the states.
The company had submitted its 510K application in November 2004.
USCOM chief executive Gary Davey said the company already had regulatory clearance and first sales in 11 other countries, including Australia. USCOM said its cardiac monitor uses ultrasound technology to cost-effectively and non-invasively measure blood flow across the cardiac valves.
The company raised AUD$16 million at $2.00 per share when it listed in 2003. At time of writing, its shares were up 5 per cent to $2.20.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
